Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for addressing dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing ADX-629, an innovative, first-in-class RASP modulator designed for oral administration, which is undergoing Phase II studies for conditions such as psoriasis, asthma, and COVID-19. Another pipeline asset, ADX-2191, a dihydrofolate reductase inhibitor, is in Phase 3 for the prevention of proliferative vitreoretinopathy and in Phase II trials for treating retinitis pigmentosa and primary vitreoretinal lymphoma. The company also holds a license agreement with Madrigal Pharmaceuticals, Inc. for the development of ADX-1612, a compound that inhibits the protein chaperome to tackle inflammatory diseases. Originally incorporated in 2004 as Aldexa Therapeutics, Inc., the company officially adopted the name Aldeyra Therapeutics, Inc. in March 2014 and is headquartered in Lexington, Massachusetts.
